Ipamorelin: A Novel Selective Peptide Boosts Growth Hormone Without Side Effects
Background
Growth hormone (GH) plays a crucial role in growth, metabolism, and body composition. While growth hormone secretagogues (GHSs), compounds that stimulate GH release, hold therapeutic promise for conditions like GH deficiency or muscle wasting, many early GHSs also triggered the release of other hormones like prolactin and cortisol, leading to undesirable side effects. This study aimed to identify and characterize a novel GHS that selectively stimulates GH release without affecting other pituitary hormones.
Results
Ipamorelin demonstrated a potent, dose-dependent stimulation of growth hormone release in rats. At its peak effect, the 0.3 mg/kg dose of Ipamorelin resulted in a 5.2-fold increase in plasma GH levels compared to saline control (p<0.001), reaching 125 ± 15 ng/mL at 30 minutes. Crucially, unlike the non-selective GHRP-6 which caused a 2.8-fold increase in prolactin and a 1.5-fold increase in cortisol (p<0.05), Ipamorelin showed no significant effect on either hormone. This selectivity was maintained even at the highest effective dose, indicating a superior safety profile compared to previous GHS compounds. The most significant finding was that Ipamorelin selectively stimulated GH release, with plasma prolactin and cortisol levels remaining indistinguishable from saline-treated controls across all tested doses (p>0.05 for all comparisons).
Why It Matters
This study marks a significant advancement by identifying Ipamorelin as the first truly selective growth hormone secretagogue, offering a cleaner pharmacological profile. The absence of significant prolactin or cortisol elevation suggests a reduced risk of side effects commonly associated with non-selective GHSs, such as hyperprolactinemia or adrenal activation. This selectivity could pave the way for Ipamorelin's clinical development as a safer therapeutic option for conditions like adult GH deficiency, sarcopenia, and cachexia. Future research should focus on long-term efficacy and safety in human clinical trials, potentially moving into Phase II studies.